Long term impact of vonoprazan‐based <i>Helicobacter pylori</i> treatment on gut microbiota and its relation to post‐treatment body weight changes

Suzuki, Shinichi; Gotoda, Takuji; Takano, Chika; Horii, Toshiki; Sugita, Tomomi; Ogura, Kyoko; Ichijima, Ryoji; Kusano, Chika; Ikehara, Hisatomo

doi:10.1111/hel.12851

Cited by 14 publications

(14 citation statements)

References 43 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared with the baseline, the alpha diversities of the gut microbiota were not altered at 1 and 8 weeks after VA dual therapy 17 . Additionally, the alpha diversity was significantly increased 1 year after VA dual therapy treatment, 31 indicating that the therapy showed no influences on the gut microbiota in the short term and improved the diversity of the gut microbiota in the long term. Our previous study indicated that no alterations of the gut microbiota were induced by L‐VA dual therapy, the diversity was decreased and the microbial composition was altered immediately after H‐VA dual therapy but was restored after 1 month 32 .…”

Section: Discussionmentioning

confidence: 85%

“…Compared with the baseline, the alpha diversities of the gut microbiota were not altered at 1 and 8 weeks after VA dual therapy. 17 Additionally, the alpha diversity was significantly increased 1 year after VA dual therapy treatment, 31 indicating that the therapy showed no influences on the gut microbiota in the short term and improved the diversity of the gut microbiota in the long term.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan‐amoxicillin dual therapy for Helicobacter pylori eradication

Ouyang

et al. 2022

Helicobacter

View full text Add to dashboard Cite

Background The oral cavity is considered a potential reservoir of Helicobacter pylori (H. pylori), and the imbalance of oral microbiota directly reflects the health of the host. We aimed to explore the relationship among oral microbiota, H. pylori infection, and vonoprazan‐amoxicillin (VA) dual therapy for H. pylori eradication. Methods Helicobacter pylori‐positive patients were randomized into low‐ or high‐dose VA dual therapy (i.e., amoxicillin 1 g b.i.d. or t.i.d. and vonoprazan 20 mg b.i.d) for 7 or 10 days. H. pylori‐negative patients served as normal controls. Saliva samples were collected from 41 H. pylori‐positive patients and 13 H. pylori‐negative patients. The oral microbiota was analyzed by 16S rRNA gene sequencing, followed by bioinformatics analysis. Results Helicobacter pylori‐positive patients had higher richness and diversity and better evenness of oral microbiota than normal controls. Beta diversity analysis estimated by Bray–Curtis or weighted UniFrac showed distinct clustering between H. pylori‐positive patients and normal controls. The number of bacterial interactions was reduced in H. pylori‐positive patients compared with that in negative patients. Forty‐one patients evaluated before and after successful H. pylori eradication were divided into low (L‐VA) and high dose (H‐VA) amoxicillin dose groups. The alpha and beta diversity of the oral microbiota between L‐VA and H‐VA patients exhibited no differences at the three time points (before eradication, after eradication, and at confirmation of H. pylori infection cure). Conclusion Helicobacter pylori infection could alter the diversity, composition, and bacterial interactions of the oral microbiota. Both L‐VA and H‐VA dual therapy showed minimal influence on the oral microbiota.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan‐amoxicillin dual therapy for Helicobacter pylori eradication

Ouyang

et al. 2022

Helicobacter

View full text Add to dashboard Cite

show abstract

“…However, no differences were observed when using VA dual therapy, possibly due to the absence of clarithromycin ( Horii et al., 2021 ). One year after treatment, the alpha diversity was increased in both groups in comparison to before eradication ( Suzuki et al., 2021 ). In Japan, the duration of VA dual therapy is 7 days due to limitations by the national medical insurance policy.…”

Section: Introductionmentioning

confidence: 88%

Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication

Ouyang

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

The combination of vonoprazan (VPZ) and amoxicillin (VA therapy) has been shown to achieve acceptable eradication rates for Helicobacter pylori (H. pylori). Herein, our aim was to explore the short-term effect of VA therapy on the gut microbiota and short-chain fatty acids (SCFAs) using human fecal samples. A total of 119 H. pylori-positive patients were randomized into low- or high-dose VA therapy (i.e., amoxicillin 1 g b.i.d. or t.i.d. and VPZ 20 mg b.i.d.) for 7 or 10 days. Thirteen H. pylori-negative patients served as controls. Fecal samples were collected from H. pylori-positive and H. pylori-negative patients. The gut microbiota and SCFAs were analyzed using 16S rRNA gene sequencing and gas chromatography–mass spectrometry, respectively. The gut microbiota in H. pylori-positive patients exhibited increased richness, diversity, and better evenness than matched patients. Fifty-three patients studied before and after H. pylori eradication were divided into low (L-VA) and high (H-VA) amoxicillin dose groups. The diversity and composition of the gut microbiota among L-VA patients exhibited no differences at the three time points. However, among H-VA patients, diversity was decreased, and the microbial composition was altered immediately after H-VA eradication but was restored by the confirmation time point. The decreased abundance of Anaerostipes, Dialister, and Lachnospira induced by H-VA was associated with altered SCFA levels. VA dual therapy for H. pylori eradication has minimal negative effects on gut microbiota and SCFAs.

show abstract

“…Alternatively, Min Li et al [38] stated in a meta-analysis that vonoprazan instead of conventional PPI-based therapies showed significantly superior eradication rates in clarithromycin-resistant strains in both randomised controlled trials (pooled eradication rates 82.0% vs 40.0%; OR, 6.83; 95% CI, 3.63-12.86; p <0.0001) and nonrandomised controlled trials (pooled eradication rates 80.8% vs 41.8%; OR, 4.98; 95% CI, 2.47-10.03; p <0.0001). Suzuki et al [39] found that vonoprazan-based H. pylori eradication was associated with a long-term impact on gut microbiota, including effects on the richness of bacterial species. According to these studies, the choice not only of antibiotics but also of the acid suppressant may play a role in eradication success.…”

Section: Original Articlementioning

confidence: 99%

Clarithromycin-based Helicobacter pylori eradication therapy is not associated with higher treatment failure compared with non-clarithromycin-based regimens in a tertiary referral hospital in Switzerland

Braendli¹,

Schindler²,

Braun³

et al. 2023

Swiss Med Wkly

View full text Add to dashboard Cite

BACKGROUND AND AIMS: Due to increasing antibiotic resistance, various Helicobacter pylori eradication regimens other than clarithromycin-based therapies have been proposed. However, detailed data on which therapies were employed and their eradication success is lacking. The purpose of this study was to analyse the response rates of different eradication therapy schemes. METHODS: In this retrospective cohort study, we analysed data of 1721 patients and included 608 patients undergoing H. pylori eradication therapy at the Department of Gastroenterology at the University Hospital Zurich between 2004 and 2018. The primary endpoint was the success rates of clarithromycin- and non-clarithromycin-containing H. pylori eradication regimens. We furthermore analysed factors with potential impact on the outcome of H. pylori eradication therapies, such as demographics, and smoking and social status. RESULTS: The most common therapy scheme (71% of all cases) was proton pump inhibitor (PPI)-amoxicillin-metronidazole, followed by PPI-amoxicillin-clarithromycin (21%) and PPI-metronidazole-clarithromycin (6%). There was no difference between the H. pylori eradication success of clarithromycin vs non-clarithromycin-containing therapies (71% vs 71%, p = 0.764). CONCLUSION: Despite increasing clarithromycin resistance globally, there was no difference in the eradication success of clarithromycin- and non-clarithromycin-containing therapy regimens in Switzerland. As varying triple therapies do not increase eradication rates in real-world settings, other primary therapy options such as quadruple therapies should be explored.

show abstract

Long term impact of vonoprazan‐based Helicobacter pylori treatment on gut microbiota and its relation to post‐treatment body weight changes

Cited by 14 publications

References 43 publications

Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan‐amoxicillin dual therapy for Helicobacter pylori eradication

Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan‐amoxicillin dual therapy for Helicobacter pylori eradication

Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication

Clarithromycin-based Helicobacter pylori eradication therapy is not associated with higher treatment failure compared with non-clarithromycin-based regimens in a tertiary referral hospital in Switzerland

Contact Info

Product

Resources

About